Organogenesis Holdings Inc (ORGO) - Total Assets
Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) holds total assets worth $509.83 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ORGO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Organogenesis Holdings Inc - Total Assets Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's total assets have evolved over time, based on quarterly financial data. See Organogenesis Holdings Inc (ORGO) shareholders funds for net asset value and shareholders' equity analysis.
Organogenesis Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Organogenesis Holdings Inc's total assets of $509.83 Million consist of 57.4% current assets and 42.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.2% |
| Accounts Receivable | $109.86 Million | 22.1% |
| Inventory | $26.22 Million | 5.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.47 Million | 2.5% |
| Goodwill | $28.77 Million | 5.8% |
Asset Composition Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Organogenesis Holdings Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Organogenesis Holdings Inc's current assets represent 57.4% of total assets in 2024, an increase from 27.8% in 2001.
- Cash Position: Cash and equivalents constituted 27.2% of total assets in 2024, up from 7.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.
Organogenesis Holdings Inc Competitors by Total Assets
Key competitors of Organogenesis Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
China | CN¥5.91 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
Organogenesis Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.32 | 3.09 | 2.56 |
| Quick Ratio | 2.88 | 2.74 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $209.43 Million | $161.23 Million | $106.13 Million |
Organogenesis Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Organogenesis Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | $497.89 Million |
| Market Capitalization | $340.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Organogenesis Holdings Inc's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Organogenesis Holdings Inc's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual total assets of Organogenesis Holdings Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $497.89 Million | +8.23% |
| 2023-12-31 | $460.02 Million | +2.37% |
| 2022-12-31 | $449.36 Million | +1.38% |
| 2021-12-31 | $443.26 Million | +52.73% |
| 2020-12-31 | $290.22 Million | +31.51% |
| 2019-12-31 | $220.69 Million | +34.83% |
| 2018-12-31 | $163.68 Million | -47.67% |
| 2017-12-31 | $312.79 Million | +0.44% |
| 2016-12-31 | $311.44 Million | +74715.66% |
| 2015-12-31 | $416.27K | -84.10% |
| 2001-12-31 | $2.62 Million | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more